Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy.

Detailed demographic and investigation data can be seen in Table 2 . Assessment of arrhythmia Fabry disease: primary versus secondary prevention devices The occurrence of any arrhythmia requiring treatment as a combined endpoint or AF alone as a single endpoint tended to be higher in Fabry patients who had a device implanted for secondary prevention, although this did not reach statistical significance due to low numbers (any arrhythmia: primary—17/36, 47% vs. secondary—10/14, 71%, p = 0.206 and AF: primary—7/36, 19% vs. secondary—4/14, 29%, p = 0.476).

also in 111,027 other papers